Chugai Pharmaceutical Co., Ltd. (4519)

Frankfurt


	Symbol		Exchange		Currency
	4519		Tokyo		JPY	Delayed
	CHGCY		OTC Markets		USD	Delayed
	4519		Frankfurt		EUR	Delayed

Currency in EUR

39.1800

+0.4100(+1.06%)

Closed29/11

Fair Value

Day's Range

38.9300

39.1800

52 wk Range

26.8700

47.0100

4519 Income Statement

Featured here, the Income Statement (earnings report) for Chugai Pharmaceutical Co., Ltd., showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

686,184

786,946

999,759

1,259,946

1,111,367

Total Revenues Growth

+18.35%

+14.68%

+27.04%

+26.02%

-11.79%

Cost Of Revenues

266,071

273,465

338,147

476,251

413,306

Gross Profit

420,113

513,481

661,612

783,695

698,061

Gross Profit Growth

+32.55%

+22.22%

+28.85%

+18.45%

-10.93%

Gross Profit Margin %

61.22%

65.25%

66.18%

62.2%

62.81%

Other Operating Expenses, Total

209,516

212,251

239,715

250,386

258,887

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+8.77%	+1.31%	+12.94%	+4.45%	+3.4%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	107,942	117,850	137,299	149,626	174,868
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	101,574	94,401	102,416	100,760	112,580
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-28,561

Operating Income

210,597

301,230

421,897

533,309

439,174

Operating Income Growth

+69.4%

+43.04%

+40.06%

+26.41%

-17.65%

EBIT Margin %

30.69%

38.28%

42.2%

42.33%

39.52%

Net Interest Expenses

420

-62

-48

-9

4,647

Net Interest Expenses Growth

+24.26%

-114.76%

+22.58%

+81.25%

+51,733.33%

Interest Expense, Total

-125

-62

-48

-61

-27

Interest And Investment Income

545

-

-

52

4,674

Other Non Operating Expenses, Total

-3,124

-2,980

-2,464

-2,134

-

EBT, Excl. Unusual Items

207,893

298,188

419,385

531,166

443,821

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-

-

-

-

EBT, Incl. Unusual Items

207,893

298,188

419,385

531,166

443,821

EBT, Incl. Unusual Items Growth

+71.18%

+43.43%

+40.64%

+26.65%

-16.44%

EBT, Incl. Unusual Items Margin

30.3%

37.89%

41.95%

42.16%

39.93%

Income Tax Expense

50,333

83,455

116,390

156,737

118,349

Net Income to Company

157,560

214,733

302,995

374,429

325,472

Minority Interest

-

-

-

-

-

Net Income

157,560

214,733

302,995

374,429

325,472

Net Income Growth

+70.36%

+36.29%

+41.1%

+23.58%

-13.08%

Net Income Margin %

22.96%

27.29%

30.31%

29.72%

29.29%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

157,560

214,733

302,995

374,429

325,472

Basic EPS - Continuing Operations

95.95

130.66

184.29

227.64

197.83

Basic EPS - Continuing Operations Growth

+70.25%

+36.18%

+41.04%

+23.53%

-13.1%

Diluted EPS - Continuing Operations

95.81

130.53

184.17

227.57

197.8

Diluted EPS - Continuing Operations Growth

+70.28%

+36.24%

+41.09%

+23.57%

-13.08%

Basic Weighted Average Shares Outstanding

1,642.14

1,643.45

1,644.15

1,644.8

1,645.21

Diluted Weighted Average Shares Outstanding

1,644.51

1,645.08

1,645.23

1,645.34

1,645.5

Dividend Per Share

32

55

76

78

80

Dividend Per Share Growth

+11.63%

+71.88%

+38.18%

+2.63%

+2.56%

EBITDA

236,998

331,606

452,765

564,743

470,914

EBITDA Growth

+68.2%

+39.92%

+36.54%

+24.73%

-16.61%

EBITDA Margin %

34.54%

42.14%

45.29%

44.82%

42.37%

EBIT